Samsung Biologics (KRX:207940) acquired a U.S. manufacturing facility from NYSE-listed GSK for $280 million, according to a company press release on Wednesday.
Shares of the contract development and manufacturing company were up over 1% in Thursday trading.
The facility has a production capacity of 60,000 liters of drug substance and takes the company's total capacity to 845,000 liters.
The company is also planning to expand the facility's capacity and upgrade it further.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments